Duration of antiretroviral therapy adherence interruption is associated with risk of virologic rebound as determined by real-time adherence monitoring in rural Uganda

Journal of Acquired Immune Deficiency Syndromes

Volumn 70, Issue 4, 2015, Pages 386-392

  Haberer, Jessica E ^a,b   Musinguzi, Nicholas ^c   Boum, Yap ^c,d   Siedner, Mark J ^a,b   Mocello, A Rain ^e   Hunt, Peter W ^e   Martin, Jeffrey N ^e   Bangsberg, David R ^a,b,f  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MBARARA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Uganda)

^d MÉDECINS SANS FRONTIÈRES   (Switzerland)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

HIV antiretroviral therapy; Real time adherence monitoring; Viral rebound

Indexed keywords

EFAVIRENZ; NEVIRAPINE; RNA; ANTIRETROVIRUS AGENT; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; REBOUND; TREATMENT DURATION; UGANDA; ADOLESCENT; BLOOD; DRUG MONITORING; HIV INFECTIONS; LONGITUDINAL STUDY; MEDICATION COMPLIANCE; RURAL POPULATION; TIME FACTOR; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-RETROVIRAL AGENTS; COHORT STUDIES; DRUG MONITORING; FEMALE; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MALE; MEDICATION ADHERENCE; RNA, VIRAL; RURAL POPULATION; TIME FACTORS; TREATMENT OUTCOME; UGANDA; VIRAL LOAD; YOUNG ADULT;

EID: 84945893494     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000737     Document Type: Article

References (26)

1. UNAIDS Report on the Global AIDS Epidemic. 2012. Available at: http://www.unaids.org/sites/default/files/media-asset/20121120-UNAIDS- Global-Report-2012-with-annexes-en-1.pdf. Accessed February 16, 2015.
2. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493-505.
3. Conway B. The role of adherence to antiretroviral therapy in the management of HIV infection. J Acquir Immune Defic Syndr. 2007;45 (suppl 1):S14-S18.
4. Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA. 2006; 296:679-690.
5. Byakika-Tusiime J, Crane J, Oyugi JH, et al. Longitudinal antiretroviral adherence in HIV+ Ugandan parents and their children initiating HAART in the MTCT-Plus family treatment model: role of depression in declining adherence over time. AIDS Behav. 2009;13(suppl 1):82-91.
6. Gill CJ, Hamer DH, Simon JL, et al. No room for complacency about adherence to antiretroviral therapy in sub-Saharan Africa. AIDS. 2005; 19:1243-1249.
7. Nachega JB, Mills EJ, Schechter M. Antiretroviral therapy adherence and retention in care in middle-income and low-income countries: current status of knowledge and research priorities. Curr Opinion HIV AIDS. 2010;5:70-77.
8. Genberg BL, Wilson IB, Bangsberg DR, et al. Patterns of antiretroviral therapy adherence and impact on HIV RNA among patients in North America. AIDS. 2012;26:1415-1423.
9. Parienti JJ, Das-Douglas M, Massari V, et al. Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels. PLoS One. 2008;3:e2783.
10. Bangsberg DR. Less than 95% adherence to nonnucleoside reversetranscriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43:939-941.
11. Gras G, Schneider MP, Cavassini M, et al. Patterns of adherence to raltegravir-based regimens and the risk of virological failure among HIVinfected patients: the RALTECAPS cohort study. J Acquir Immune Defic Syndr. 2012;61:265-269.
12. Nelson M, Girard PM, Demasi R, et al. Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS data. J Antimicrob Chemother. 2010;65:1505-1509.
13. Shuter J, Sarlo JA, Kanmaz TJ, et al. HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%. J Acquir Immune Defic Syndr. 2007;45:4-8.
14. Oyugi JH, Byakika-Tusiime J, Ragland K, et al. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS. 2007;21:965-971.
15. Kerr T, Walsh J, Lloyd-Smith E, et al. Measuring adherence to highly active antiretroviral therapy: implications for research and practice. Curr HIV/AIDS Rep. 2005;2:200-205.
16. Bangsberg DR. Preventing HIV antiretroviral resistance through better monitoring of treatment adherence. J Infect Dis. 2008;197(suppl 3): S272-S278.
17. Haberer JE, Kiwanuka J, Nansera D, et al. Realtime adherence monitoring of antiretroviral therapy among HIV-infected adults and children in rural Uganda. AIDS. 2013;27:2166-2168.
18. Lima VD, Bangsberg DR, Harrigan PR, et al. Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level. J Acquir Immune Defic Syndr. 2010;55:460-465.
19. Martin M, Del Cacho E, Codina C, et al. Relationship between adherence level, type of the antiretroviral regimen, and plasma HIV type 1 RNA viral load: a prospective cohort study. AIDS Res Hum Retroviruses. 2008; 24:1263-1268.
20. Nachega JB, Hislop M, Dowdy DW, et al. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med. 2007;146:564-573.
21. Rosenblum M, Deeks SG, van der Laan M, et al. The risk of virologic failure decreases with duration of HIV suppression, at greater than 50% adherence to antiretroviral therapy. PLoS One. 2009;4:e7196.
22. Smith PF, DiCenzo R, Morse GD. Clinical pharmacokinetics of nonnucleoside reverse transcriptase inhibitors. Clin Pharmacokinet. 2001;40: 893-905.
23. Simoni JM, Kurth AE, Pearson CR, et al. Self-report measures of antiretroviral therapy adherence: a review with recommendations for HIV research and clinical management. AIDS Behav. 2006;10:227-245.
24. Petersen ML, LeDell E, Schwab J, Sarovar V, et al. Super Learner Analysis of Electronic Adherence Data Improves Viral Prediction and May Provide Strategies for Selective HIV RNA Monitoring. J Acquir Immune Defic Syndr. 2015;69:109-118.
25. Lester RT, Ritvo P, Mills EJ, et al. Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lancet. 2010;376:1838-1845.
26. Pop-Eleches C, Thirumurthy H, Habyarimana JP, et al. Mobile phone technologies improve adherence to antiretroviral treatment in a resourcelimited setting: a randomized controlled trial of text message reminders. AIDS. 2011;25:825-834.